A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT05936151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05936151
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Italy, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05936151. Randomized; double masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-10-01 (actual). Results posted on 2026-11-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Condition
Overweight or Obesity
Intervention (Drug)
Retatrutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05936151
Content hash
69505d3ae5763a6478f80c5c017fd1adbd4d28531fc3cf5dee964f3eecf83a54